AstraZeneca Announces Acquisition of McMaster-Supported Fusion Pharmaceuticals for $2.4 Billion (US)
A cancer therapy and diagnostics company that grew from a McMaster professor’s idea into a clinical-stage biopharmaceutical company is being acquired by global pharmaceuticals giant AstraZeneca in a deal valued at as much as $2.4 billion…